MaxCyte, Inc. Notification of AGM and Audit Declaration (9794B)

TIDMMXCT TIDMTTM

RNS Number : 9794B

MaxCyte, Inc.

14 October 2020

Notification of Annual General Meeting and Declaration of Audit Remuneration

Gaithersburg, Maryland - 14 October 2020: MaxCyte, Inc. (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, announces that formal notice and resolutions of the Company's Annual General Meeting (AGM), have been circulated to Shareholders.

These documents are also available in electronic form on the Company's website: www.maxcyte.com.

In order to assist investors in considering the resolutions proposed ahead of the AGM, the Company notes that the remuneration of the Company's auditors, Cohn Rezhnick LLC, for audit-related services relating to the 2019 financial year, amounted to approximately $137,000.

The Annual General Meeting of Stockholders is planned to be held at 11 a.m. EDT on 30 October 2020 at 21 Firstfield Road, Suite 202, Gaithersburg, MD 20878, USA.

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com .

###

Contacts:

 
 MaxCyte Inc. 
  Doug Doerfler, Chief Executive Officer 
  Amanda Murphy, Chief Financial Officer                             [phone] 
 Nominated Adviser and Joint Corporate 
  Broker 
  Panmure Gordon 
  Emma Earl 
  Freddy Crossley 
  Corporate Broking 
  Rupert Dearden                                                       [phone] 
 Joint Corporate Broker 
  Numis Securities Limited 
  James Black 
  Duncan Monteith                                                      [phone] 
 
   Financial PR Adviser                                                [phone] 
   Consilium Strategic Communications                                  maxcyte@consilium-com 
   Mary-Jane Elliott 
   Chris Welsh 
 
   -------------------------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFLFERIFLVLII

(END) Dow Jones Newswires

October 14, 2020 02:00 ET (06:00 GMT)